T-DM1治疗HER2阳性乳腺癌后非肝硬化性门静脉高压的CT深度学习脾体积评估
本研究回顾性纳入2001至2020年接受T-DM1或拉帕替尼联合卡培他滨治疗的HER2阳性乳腺癌患者,利用深度学习算法测量CT脾体积并评估门静脉高压征象。结果显示T-DM1组脾体积进行性增加,脾大、胃食管静脉曲张和自发性门体分流的发生率均显著高于对照组,提示T-DM1与非肝硬化性门静脉高压相关。
要点
- T-DM1治疗中应关注脾体积进行性增大及门静脉高压征象。
- CT可见胃食管静脉曲张和自发性门体分流,需在报告中提示。
- 深度学习测量脾体积可用于监测T-DM1相关门静脉高压。
关键影像表现/征象
- T-DM1组脾体积随治疗进行性增加,第33治疗周期时变化为104%±5,对照组为-1%±6(P < .001)。
- T-DM1组脾大发生率为46%(51/111),对照组为3%(4/122)(P < .001)。
- T-DM1组胃食管静脉曲张发生率为11%(12/111),对照组为1%(1/122)(P < .001)。
- T-DM1组自发性门体分流发生率为27%(30/111),对照组为1%(1/122)(P < .001)。
临床应用与阅片要点
- 对接受T-DM1治疗的HER2阳性乳腺癌患者,阅片时应关注脾体积变化及门静脉高压征象。
- 发现脾大、胃食管静脉曲张或自发性门体分流时,应提示临床T-DM1相关非肝硬化性门静脉高压可能。
- 建议使用深度学习算法测量脾体积以客观监测变化。
局限性
- 回顾性单中心研究,可能存在选择偏倚。
- 样本量有限,需多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for use in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Case reports have suggested an association between T-DM1 and portal hypertension. Purpose To evaluate the association of T-DM1 therapy with spleen volume changes and portal hypertension on CT scans and clinical findings compared with lapatinib and capecitabine therapy. Materials and Methods Patients with HER2-positive breast cancer who were administered at least two cycles of T-DM1 or lapatinib and capecitabine (controls) in a tertiary institution from 2001 to 2020 and who underwent CT before initial treatment and at least once during treatment were retrospectively enrolled. Spleen volume changes and the signs of portal hypertension (gastroesophageal varix [GEV], spontaneous portosystemic shunt [SPSS], and ascites) were evaluated at contrast-enhanced CT. Patients were followed until treatment ended or for 2 years after the start of treatment. Spleen volume changes were measured with a deep learning algorithm and evaluated by using a linear mixed model. The incidences of splenomegaly and portal hypertension were compared between the T-DM1 and control groups by using a χ2 test or Fisher exact test. Results The T-DM1 group included 111 patients (mean age, 54 years ± 11 [SD]; 111 women) and the control group included 122 patients (mean age, 50 years ± 9; 121 women). Spleen volume progressively increased with T-DM1 therapy but was constant in the control group (104% ± 5 vs -1% ± 6 at the 33rd treatment cycle, respectively; P < .001). Incidences of splenomegaly (46% [51 of 111] vs 3% [four of 122] of patients; P < .001), GEV (11% [12 of 111] vs 1% [one of 122] of patients; P < .001), and SPSS (27% [30 of 111] vs 1% [one of 122] of patients; P < .001) were higher in the T-DM1 group than in the control group. Conclusion Trastuzumab emtansine therapy was associated with noncirrhotic portal hypertension at CT, with higher incidences of splenomegaly, gastroesophageal varix, and spontaneous portosystemic shunt than those with lapatinib and capecitabine therapy. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Choi, Lee, Jung, et al. Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning-measured Spleen Volume at CT. Radiology. 2022. PMID: 35943338. doi:10.1148/radiol.220536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。